Swiss germ-cell cancer consensus recommendations
Jörg Beyer, Dominik Berthold, Peter-Karl Bode, Richard Cathomas, Christian D Fankhauser, Stefanie Fischer, Silke Gillessen, Tobias Gross, Thomas Hermanns, Friedemann Honecker, Anja Lorch, Aurelius Omlin, Alexandros Papachristofilou, Beat Roth, Christian Rothermundt, Roland Seiler, Martin Spahn, Frank Stenner & Emanuel Bührer
|
abstract
|
Approximately 420 men are diagnosed with germ-cell cancer (GCC) in
Switzerland each year. Recent international guidelines outline
management issues, but many aspects remain controversial in an area
of highly individualised treatments. Even more than in other tumour
types, in GCC the challenge is to choose exactly the correct
treatment for an individual patient. Overtreatment in patients
likely to be cured must be avoided to reduce long-term toxicities.
On the other hand, treatment intensification is required in patients
presenting with adverse prognostic factors. Therefore, referral to
expert centres or consultations with an expert for a second opinion
is strongly recommended. In 2020, Swiss experts discussed their
strategies in a consensus meeting during the virtual Swiss Oncology
and Haematology Congress (SOHC) in order to harmonise their concepts
and to suggest optimal strategies for the management of GCC patients
in Switzerland. Votes on controversial issues were obtained and are
presented in this review wherever applicable.
|
| |
|
|
citation
|
Beyer J, Berthold D, Bode P K, Cathomas R, Fankhauser C D, Fischer
S, Gillessen S, Gross T, Hermanns T, Honecker F, Lorch A, Omlin A,
Papachristofilou A, Roth B, Rothermundt C, Seiler R, Spahn M,
Stenner F, Bührer E. Swiss germ-cell cancer consensus
recommendations. Swiss Med Wkly 2021; 151:.
|
| |
|
|
type
|
journal paper/review (English)
|
|
date of publishing
|
23-08-2021
|
|
journal title
|
Swiss Med Wkly (151/33-34)
|
|
ISSN electronic
|
1424-3997
|
|
PubMed
|
34495606
|
|
DOI
|
10.4414/SMW.2021.w30023
|
additional links & downloads
